62 related articles for article (PubMed ID: 20595016)
1. Drug penetration model of vinblastine-treated Caco-2 cultures.
Hellinger E; Bakk ML; Pócza P; Tihanyi K; Vastag M
Eur J Pharm Sci; 2010 Sep; 41(1):96-106. PubMed ID: 20595016
[TBL] [Abstract][Full Text] [Related]
2. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
3. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
4. Expression levels of human P-glycoprotein in in vitro cell lines: correlation between mRNA and protein levels for P-glycoprotein expressed in cells.
Shirasaka Y; Konishi R; Funami N; Kadowaki Y; Nagai Y; Sakaeda T; Yamashita S
Biopharm Drug Dispos; 2009 Apr; 30(3):149-52. PubMed ID: 19243013
[TBL] [Abstract][Full Text] [Related]
5. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery.
Balimane PV; Patel K; Marino A; Chong S
Eur J Pharm Biopharm; 2004 Jul; 58(1):99-105. PubMed ID: 15207543
[TBL] [Abstract][Full Text] [Related]
6. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines.
Siissalo S; Laitinen L; Koljonen M; Vellonen KS; Kortejärvi H; Urtti A; Hirvonen J; Kaukonen AM
Eur J Pharm Biopharm; 2007 Sep; 67(2):548-54. PubMed ID: 17475454
[TBL] [Abstract][Full Text] [Related]
7. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models.
Hellinger E; Veszelka S; Tóth AE; Walter F; Kittel A; Bakk ML; Tihanyi K; Háda V; Nakagawa S; Duy TD; Niwa M; Deli MA; Vastag M
Eur J Pharm Biopharm; 2012 Oct; 82(2):340-51. PubMed ID: 22906709
[TBL] [Abstract][Full Text] [Related]
8. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
9. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
Shirasaka Y; Kawasaki M; Sakane T; Omatsu H; Moriya Y; Nakamura T; Sakaeda T; Okumura K; Langguth P; Yamashita S
Drug Metab Pharmacokinet; 2006 Oct; 21(5):414-23. PubMed ID: 17072095
[TBL] [Abstract][Full Text] [Related]
10. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.
Roger E; Lagarce F; Garcion E; Benoit JP
Eur J Pharm Sci; 2010 Aug; 40(5):422-9. PubMed ID: 20438839
[TBL] [Abstract][Full Text] [Related]
12. Effects of capsaicin on P-gp function and expression in Caco-2 cells.
Han Y; Tan TM; Lim LY
Biochem Pharmacol; 2006 Jun; 71(12):1727-34. PubMed ID: 16674925
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells.
Brouillard F; Tondelier D; Edelman A; Baudouin-Legros M
Cancer Res; 2001 Feb; 61(4):1693-8. PubMed ID: 11245485
[TBL] [Abstract][Full Text] [Related]
14. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide does not interact with P-glycoprotein.
Zimmermann C; Gutmann H; Drewe J
Cancer Chemother Pharmacol; 2006 May; 57(5):599-606. PubMed ID: 16136308
[TBL] [Abstract][Full Text] [Related]
16. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM
Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822
[TBL] [Abstract][Full Text] [Related]
17. Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells.
Belliard AM; Tardivel S; Farinotti R; Lacour B; Leroy C
J Pharm Pharmacol; 2002 Aug; 54(8):1103-9. PubMed ID: 12195825
[TBL] [Abstract][Full Text] [Related]
18. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
20. Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.
Hilgendorf C; Spahn-Langguth H; Rhedin M; Regårdh CG; Löwenadler B; Langguth P
Mol Pharm; 2005; 2(1):64-73. PubMed ID: 15804179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
